WO1992018112A1 - Method of preventing nmda receptor complex-mediated neuronal damage - Google Patents
Method of preventing nmda receptor complex-mediated neuronal damage Download PDFInfo
- Publication number
- WO1992018112A1 WO1992018112A1 PCT/US1992/003196 US9203196W WO9218112A1 WO 1992018112 A1 WO1992018112 A1 WO 1992018112A1 US 9203196 W US9203196 W US 9203196W WO 9218112 A1 WO9218112 A1 WO 9218112A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nmda
- medicament
- nitroprusside
- neuronal damage
- mammal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- This invention relates to the treatment of nervous system disorders, particularly disorders mediated by the N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptor complex.
- NMDA N-methyl-D-aspartate
- Glutamate has been implicated as a significant factor in the neurotoxicity associated with hypoxic- ischemic encephalopathy, anoxia, hypoglycemia, seizures, trauma, and several degenerative neurological disorders such as the AIDS dementia complex and other neurological manifestations of AIDS, Huntingto ⁇ s disease and Parkinsonism (Hahn et al., Proc. Natl . Acad. Sci . USA 85:6556, 1988; Choi, Neuron 1:623, 1988; Rothman et al., Trends Neurosci . 10:299, 1987; Meldrum et al., Trends Pharm. Sci . 3.1:379, 1990).
- one aspect of the invention features a medicament for reducing NMDA receptor complex-mediated neuronal damage in a mammal, comprising one of the above-described compounds to the mammal.
- oxidation of the NMDA receptor is known to protect against NMDA receptor-mediated neuronal damage (see, e.g., PCT WO91/02180) .
- the active species of nitroglycerin and nitroprusside is nitric oxide (NO) (see, e.g., Garthwaite et al. (Trends in Neurosciences 14.:60, 1991). Accordingly, one possible mechanism for the protective effect that I have discovered is nitric oxide-induced oxidation of the NMDA receptor-channel complex.
- a second aspect of the invention features a medicament for reducing NMDA receptor complex- mediated neuronal damage by administering a nitric-oxide generating compound, in a concentration effective to cause such reduction.
- This second aspect of the invention is founded on the premise that NO acts on the NMDA receptor-channel complex to protect against NMDA receptor-mediated damage.
- the mammal is a human infected with a virus affecting the nervous system — e.g., measles or human immunodeficiency virus (HIV) ; and the human manifests symptoms of the AIDS related complex or acquired immunodeficiency syndrome.
- a virus affecting the nervous system e.g., measles or human immunodeficiency virus (HIV)
- HIV human immunodeficiency virus
- the mammal has a disorder such as hypoxia, ischemia, hypoglycemia, trauma, seizures or stroke, or is likely to become subject to these, i.e., could be treated prophylactically.
- NMDA receptor-mediated neuronal damage any neuronal injury which results from stimulation or costimulation of the NMDA receptor-channel complex, a receptor-channel complex which is found on a subset of mammalian neurons and which includes a molecule that interacts with NMDA or similar agonists (see below) to induce neuron excitation.
- a nitric oxide-generating compound is meant any compound which produces a sufficient amount of nitric oxide upon administration to a mammal to reduce neuronal damage or injury.
- Useful compounds of the second aspect of the instant invention include any nitric oxide-generating compounds.
- Verification that a particular compound provides protective oxidation of the NMDA receptor itself is a step well understood by those skilled in the art (see, e.g., PCT WO 91/02810).
- the literature describes the enzyme, NO synthase, which produces nitric oxide in certain cell types; this enzyme and its role in neuronal function is discussed in, e.g., Garthwaite et al. (Trends in Neurosciences 14:60. 1991) and Hope et al. (Proc. Natl . Acad. Sci . USA 88:2811, 1991).
- the two preferred compounds of the first aspect of the invention i.e., nitroglycerin and nitroprusside
- provide the advantage of a proven record of safe human administration i.e., for treatment for cardiovascular disorders.
- Disorders which may be treated by the method of the invention include hypoxia, ischemia, hypoglycemia, trauma, seizures, stroke, AIDS dementia and other neurological manifestations of HIV (see, e.g., USSN 571,949) or other viruses affecting the nervous system, and, generally, acute and chronic neurodegenerative disorders, including, but not limited to Parkinson's disease, Alzheimer's disease, and Huntington's disease .
- the ability of NO to be transported and to cross cell membranes facilitates therapies according to the invention.
- Fig. 1 is a bar graph showing that nitroprusside prevents NMDA-mediated neurotoxicity.
- Fig. 2 is a bar graph of intracellular Ca concentration (i.e., [Ca 2+ ]i) in (a) control cells and in the presence of (b) NMDA alone, (c) NMDA after dithiothreitol (DTT) , and (d) NMDA after DTT and nitroprusside.
- NMDA intracellular Ca concentration
- the present invention is based on the finding that the compounds nitroprusside and nitroglycerin reduce NMDA receptor complex-mediated neuronal damage (see below) .
- This reduction in damage may be due to oxidation of the NMDA receptor at the redox modulatory site.
- the reduction is associated with a decrease in NMDA receptor- operated channel activation by excitatory amino acids (such as NMDA) and a concomitant decrease in intracellular calcium leading to neurotoxicity.
- glutamate-related compounds An increased level of one or more glutamate- related compounds is associated with many neurodegenerative disorders (e.g., those listed above).
- neuronal injury may result from stimulation of the NMDA receptor-channel complex by other excitatory amino acids, such as aspartate, quinolinate, homocysteic acid, cysteine sulphinic acid, or cysteic acid, or from stimulation by excitatory peptides, such as N-acetyl aspartyl glutamate.
- Nitroglycerin (1,2,3-propanetriol trinitrate or glyceryl trinitrate or GTN) , nitroprusside and N0- generating derivatives of either one of those compounds are considered to be particularly useful in the invention.
- Compounds of the second aspect of the invention may be tested for efficacy in reducing neuronal damage using the assays described below —i.e. in assays of NMDA evoked ionic current (see, e.g., PCT WO 91/02810), in assays of NMDA- evoked increases in intracellular Ca 2+ (see below) , or in assays of neuronal cell death (see below) .
- An effective compound will cause a decrease in ionic current, intracellular Ca 2+ concentration, or in neuronal cell death, respectively.
- Compounds most preferred in the invention are those which effect the greatest protection of neurons from NMDA receptor complex-mediated injury, e.g., that injury resulting from stimulation of the NMDA receptor by NMDA(as shown below) or other excitatory amino acids or stimulation by excitatory peptides, such as N-acetyl aspartyl glutamate.
- NMDA neuropeptide complex-mediated injury
- excitatory amino acids or stimulation by excitatory peptides such as N-acetyl aspartyl glutamate.
- Neonatal cortical neurons were prepared according to the general method of Snodgrass et al. (1980) Brain Res. 190:123-138: and Rosenberg et al (1988) J. Neurosci. 8.:2887-2899. Cultures are monitored following a brief exposure (5 minutes) to lOO ⁇ M NMDA, or to 5mM DTT (for 5 minutes) followed by lOO ⁇ M NMDA (for 5 additional minutes), and overnight incubation (i.e., 16 to 24 hours) .
- a compound may be tested for utility in the method of the invention using any type of neuronal cell from the central nervous system, as long as the cell can be isolated intact by conventional techniques.
- cortical neuron cultures are used above, retinal ganglion cell neurons, spinal cord neurons, cerebellar granular neurons, or any neuron containing NMDA receptors (e.g., neurons from other regions of the cortex) may also be used. Such neurons may be prenatal or postnatal.
- NMDA receptors e.g., neurons from other regions of the cortex
- Such neurons may be prenatal or postnatal.
- the compound nitroprusside was tested for its ability to increase survival of neonatal cortical neurons.
- the neuronal cells were incubated for 16-24 hours at 37°C in a humidified atmosphere of 5% C0 2 and 95% air.
- NMDA neuronal cell neurotoxicity
- An analysis of variance was used to test for significance; this analysis was followed by a Sheffe test for multiple comparison of means (Hahn et al., 1988, supra) .
- Doses of nitroprusside as low as O.lnM are expected to have neuroprotective effects.
- the concentration of intracellular free Ca 2+ ([Ca + ]i) is measured in neonatal cortical neurons by digital imaging microscopy with the Ca 2+ sensitive fluorescent dye fura 2, as follows. The same cortical neuronal cultures as described above are used. During Ca + measurements, unless otherwise stated the fluid bathing the neurons consists of Hanks' balanced salts: 137.6 mM NaCl, 1 mM NaHC0 3 , 0.34 mM Na 2 HP0 4 , 0.44mM
- the dye is loaded, trapped, and deesterified within 1 hour, as determined by stable fluorescence ratios and the effect of the Ca + ionophore ionomycin on [Ca 2+ ]i is measured.
- the cells are incubated in a solution of Hepes-buffered saline with Hanks' balanced salts.
- the [Ca + ]i is calculated from ratio images that are obtained by measuring the fluorescence at 500 nm that is excited by 350 and 380 nm light with a DAGE MTI 66 SIT or QUANTEX QX-100 Intensified CCD camera mounted on a Zeiss Axiovert 35 microscope. Exposure time for each picture is 500 ms.
- Nitroprusside Decreases the NMDA-Mediated Increase in the Intracellular Concentration of Ca
- NMDA-receptor mediated neurotoxicity has been shown to involve an increase in intracellular Ca 2+ concentration.
- the increase in [Ca ]i was documented in the following experiment.
- Intracellular Ca 2+ was measured as described above.
- Application of lO ⁇ M NMDA produced a striking increase in [Ca 2+ ]i [Fig. 2, columns 2-5(b) ] .
- levels following NMDA addition increased to 200nM.
- Verification that the effect at issue involves the NMDA redox site can be provided as follows.
- a maximal chemical oxidation with DTNB abrogates the effect of nitroprusside, strongly suggesting that nitroprusside is acting in the same manner under these conditions (i.e., as an oxidizing agent) because it has no further effect after DTNB oxidation of the redox modulatory site of the NMDA receptor-channel complex. It should be noted that once the redox modulatory site is oxidized or reduced, even after subsequent wash out of the redox agent, the site remains in this state until another effective redox agent is introduced. Therapy
- compounds of the invention may be administered by any of a number of routes in an amount sufficient to attenuate an NMDA- evoked ionic current or a rise in [Ca 2+ ]i, or neurotoxicity.
- the compound may be included in a pharmaceutical preparation, using a pharmaceutical carrier (e.g., physiological saline); the exact formulation of the therapeutic mixture depends upon the route of administration.
- a pharmaceutical carrier e.g., physiological saline
- the compound is administered orally or intravenously, but it may also be administered sublingually, by spray, by transdermal patch, or by ointment.
- nitroglycerine or their derivatives including all those preparations commercially available, e.g., those listed in the Physician' ⁇ Desk Reference (1991) under coronary vasodilators or under nitroglycerin or nitroglycerin intravenous and including isosorbide mononitrate, isosorbide dinitrate, nitroglycerin sublingual, NT-1, Niotrocor, Nitroderm, Nitrodisc, Nitro-dur, Nitro-Dur II, Nitrofilm, Nitrogard, Nitroglin, Nitropen, Tridil, and 6- chloro-2-pyridylmethyl nitrate) are administered at 0.01- lOOOmg/day, in divided doses.
- nitric oxide-generating compounds determined to be an effective neuroprotective agent by the assays described herein, is administered orally, intravenously, sublingually, by spray, or by transder al patch or ointment at a dosage suitable to reduce neuronal damage, or NMDA evoked ionic current or increased [Ca 2+ ]i.
- such compounds are administered in dosages of 0.1-5 mg/day in divided doses.
- the compounds of the invention can be utilized to protect against a number of neurotoxic disorders caused by elevated levels of glutamate or related compounds. Such neurotoxic disorders include ischemia, hypoxia, hypoglycemia, trauma, epilepsy, Huntington's disease, and Alzheimer's disease and other neurodegenerative disorders.
- the method of the invention is ' particularly preferred for the treatment of AIDS dementia and other neurological manifestations of the AIDS virus. The method may also be used for reduction of neuronal damage resulting from infection with other viruses which cause damage to the nervous system.
- Embodiments The method described herein is useful for reducing neuronal injury in any mammal having NMDA receptors. Treatment of neuronal damage in humans is the preferred utility; but the method may also be employed successfully for veterinary purposes.
Abstract
Disclosed is a medicament for reducing NMDA receptor-mediated neuronal damage in a mammal comprising a nitric-oxide generating compound, or a physiologically acceptable salt thereof, in a concentration effective to cause such reduction. Also disclosed is a medicament for reducing NMDA receptor-mediated neuronal damage in a mammal comprising nitroprusside, nitroglycerin, or a derivative of one of those compounds, in a concentration effective to cause such reduction.
Description
METHOD OF PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE Background of the Invention This invention relates to the treatment of nervous system disorders, particularly disorders mediated by the N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptor complex.
Glutamate has been implicated as a significant factor in the neurotoxicity associated with hypoxic- ischemic encephalopathy, anoxia, hypoglycemia, seizures, trauma, and several degenerative neurological disorders such as the AIDS dementia complex and other neurological manifestations of AIDS, Huntingto^s disease and Parkinsonism (Hahn et al., Proc. Natl . Acad. Sci . USA 85:6556, 1988; Choi, Neuron 1:623, 1988; Rothman et al., Trends Neurosci . 10:299, 1987; Meldrum et al., Trends Pharm. Sci . 3.1:379, 1990). In many central neurons the predominant form of this neurotoxicity appears to be mediated by activation of the NMDA subtype of glutamate receptor and subsequent influx of excessive Ca2+ (Choi, ibid; Weiss et al., Science 247:1474. 1990).
Summary of the Invention I have discovered that certain compounds protect neurons against NMDA receptor-mediated neuronal damage. Specifically, nitroglyσerin, nitroprusside, and their derivatives provide such protection. Thus, one aspect of the invention features a medicament for reducing NMDA receptor complex-mediated neuronal damage in a mammal, comprising one of the above-described compounds to the mammal.
With regard to the compounds of the first aspect of the invention, I do not wish to bind myself to any particular theory or mechanism of action. However,
oxidation of the NMDA receptor is known to protect against NMDA receptor-mediated neuronal damage (see, e.g., PCT WO91/02180) . It is also known that the active species of nitroglycerin and nitroprusside is nitric oxide (NO) (see, e.g., Garthwaite et al. (Trends in Neurosciences 14.:60, 1991). Accordingly, one possible mechanism for the protective effect that I have discovered is nitric oxide-induced oxidation of the NMDA receptor-channel complex. Accordingly, a second aspect of the invention features a medicament for reducing NMDA receptor complex- mediated neuronal damage by administering a nitric-oxide generating compound, in a concentration effective to cause such reduction. This second aspect of the invention is founded on the premise that NO acts on the NMDA receptor-channel complex to protect against NMDA receptor-mediated damage.
In preferred embodiments of both aspects of the invention, the mammal is a human infected with a virus affecting the nervous system — e.g., measles or human immunodeficiency virus (HIV) ; and the human manifests symptoms of the AIDS related complex or acquired immunodeficiency syndrome. Alternatively, the mammal has a disorder such as hypoxia, ischemia, hypoglycemia, trauma, seizures or stroke, or is likely to become subject to these, i.e., could be treated prophylactically.
By "NMDA receptor-mediated neuronal damage" is meant any neuronal injury which results from stimulation or costimulation of the NMDA receptor-channel complex, a receptor-channel complex which is found on a subset of mammalian neurons and which includes a molecule that interacts with NMDA or similar agonists (see below) to induce neuron excitation.
By a "nitric oxide-generating compound" is meant any compound which produces a sufficient amount of nitric oxide upon administration to a mammal to reduce neuronal damage or injury. Useful compounds of the second aspect of the instant invention include any nitric oxide-generating compounds. Verification that a particular compound provides protective oxidation of the NMDA receptor itself is a step well understood by those skilled in the art (see, e.g., PCT WO 91/02810). Moreover, applicant notes that the literature describes the enzyme, NO synthase, which produces nitric oxide in certain cell types; this enzyme and its role in neuronal function is discussed in, e.g., Garthwaite et al. (Trends in Neurosciences 14:60. 1991) and Hope et al. (Proc. Natl . Acad. Sci . USA 88:2811, 1991).
The two preferred compounds of the first aspect of the invention (i.e., nitroglycerin and nitroprusside) provide the advantage of a proven record of safe human administration (i.e., for treatment for cardiovascular disorders) .
Disorders which may be treated by the method of the invention include hypoxia, ischemia, hypoglycemia, trauma, seizures, stroke, AIDS dementia and other neurological manifestations of HIV (see, e.g., USSN 571,949) or other viruses affecting the nervous system, and, generally, acute and chronic neurodegenerative disorders, including, but not limited to Parkinson's disease, Alzheimer's disease, and Huntington's disease . Regarding compounds according to the second aspect of the invention, the ability of NO to be transported and to cross cell membranes facilitates therapies according to the invention.
Other features and advantages of the invention will be apparent from the following detailed description and from the claims.
Detailed Description The drawings are first briefly described. Drawings
Fig. 1 is a bar graph showing that nitroprusside prevents NMDA-mediated neurotoxicity.
Fig. 2 is a bar graph of intracellular Ca concentration (i.e., [Ca2+]i) in (a) control cells and in the presence of (b) NMDA alone, (c) NMDA after dithiothreitol (DTT) , and (d) NMDA after DTT and nitroprusside.
The present invention is based on the finding that the compounds nitroprusside and nitroglycerin reduce NMDA receptor complex-mediated neuronal damage (see below) . This reduction in damage may be due to oxidation of the NMDA receptor at the redox modulatory site. The reduction is associated with a decrease in NMDA receptor- operated channel activation by excitatory amino acids (such as NMDA) and a concomitant decrease in intracellular calcium leading to neurotoxicity.
An increased level of one or more glutamate- related compounds is associated with many neurodegenerative disorders (e.g., those listed above). In addition to glutamate itself, neuronal injury may result from stimulation of the NMDA receptor-channel complex by other excitatory amino acids, such as aspartate, quinolinate, homocysteic acid, cysteine sulphinic acid, or cysteic acid, or from stimulation by excitatory peptides, such as N-acetyl aspartyl glutamate.
Nitroglycerin (1,2,3-propanetriol trinitrate or glyceryl trinitrate or GTN) , nitroprusside and N0- generating derivatives of either one of those compounds
are considered to be particularly useful in the invention.
Compounds of the second aspect of the invention (i.e., nitric oxide-generating compounds and their derivatives) may be tested for efficacy in reducing neuronal damage using the assays described below —i.e. in assays of NMDA evoked ionic current (see, e.g., PCT WO 91/02810), in assays of NMDA- evoked increases in intracellular Ca2+ (see below) , or in assays of neuronal cell death (see below) . An effective compound will cause a decrease in ionic current, intracellular Ca2+ concentration, or in neuronal cell death, respectively. Compounds most preferred in the invention are those which effect the greatest protection of neurons from NMDA receptor complex-mediated injury, e.g., that injury resulting from stimulation of the NMDA receptor by NMDA(as shown below) or other excitatory amino acids or stimulation by excitatory peptides, such as N-acetyl aspartyl glutamate. Assay for Neuronal Cell Function and Death
To test compounds for their ability to prevent neurotoxicity, neuronal cell death may be assayed as follows. Neonatal cortical neurons were prepared according to the general method of Snodgrass et al. (1980) Brain Res. 190:123-138: and Rosenberg et al (1988) J. Neurosci. 8.:2887-2899. Cultures are monitored following a brief exposure (5 minutes) to lOOμM NMDA, or to 5mM DTT (for 5 minutes) followed by lOOμM NMDA (for 5 additional minutes), and overnight incubation (i.e., 16 to 24 hours) . Experiments in vivo suggest that a transient reducing state exists in the brain following stroke; the introduction of the chemical reducing agent DTT may mimic this reducing environment, increasing the similarity of the .in vitro assay to the n vivo situation. The candidate compound is tested by addition
(e.g., in a series of concentrations ranging from O.lnM - lO M) after DTT treatment but before NMDA treatment. Incubations last 16-24 h at 37βC in an atmosphere of 5% C02/95% air. Neuronal cultures are scored for cell survival after overnight incubation because NMDA toxicity is often delayed by several hours following NMDA exposure. The ability of cortical neurons to maintain phase-bright appearance and exclude trypan blue is used as an index of survival (Rosenberg et al. , Neurosci. Lett. 101: 162-168, 1989).
A compound may be tested for utility in the method of the invention using any type of neuronal cell from the central nervous system, as long as the cell can be isolated intact by conventional techniques. Although cortical neuron cultures are used above, retinal ganglion cell neurons, spinal cord neurons, cerebellar granular neurons, or any neuron containing NMDA receptors (e.g., neurons from other regions of the cortex) may also be used. Such neurons may be prenatal or postnatal. There now follows an example of a compound useful in the method of the invention and an illustration of its efficacy in reducing neuronal damage. This example is provided to illustrate the invention and should not be construed as limiting. Nitroprusside Prevents NMDA Receptor-Mediated Neurotoxicity
Using the assay described above, the compound nitroprusside was tested for its ability to increase survival of neonatal cortical neurons. The neuronal cells were incubated for 16-24 hours at 37°C in a humidified atmosphere of 5% C02 and 95% air.
As shown in Fig. 1, brief treatment (5 minutes) with NMDA (100/iM) produced significant neuronal cell neurotoxicity (P < 0.01, indicated by an asterisk) after overnight incubation [compare Fig. 1, column 1 (untreated
control neurons) and column 2 (neurons treated with NMDA)]. A 5 minute exposure to 0.5mM DTT (prior to the brief treatment with NMDA) further increased neurotoxicity [compare Fig. 1, column 2 (neurons treated with NMDA) with column 3 (neurons treated with DTT followed by NMDA)]. In additional cultures, nitroprusside was added for 5 minutes (after DTT exposure but prior to NMDA treatment) to the growth media to a final concentration of lμM-1 mM. Nitroprusside prevented neuronal cell death resulting from the combination of NMDA and DTT [compare Fig. 1, column 3 (neurons treated with DTT followed by NMDA) with column 4 (neurons treated with DTT followed by nitroprusside followed by NMDA) ] . Increased neuronal survival at ImM nitroprusside (Fig. 1, column 4) reached statistical significance compared to the control (Fig. 1, column 1) . An analysis of variance was used to test for significance; this analysis was followed by a Sheffe test for multiple comparison of means (Hahn et al., 1988, supra) . Doses of nitroprusside as low as O.lnM are expected to have neuroprotective effects. Measurement of Intracellular Ca2*
The concentration of intracellular free Ca2+ ([Ca +]i) is measured in neonatal cortical neurons by digital imaging microscopy with the Ca2+ sensitive fluorescent dye fura 2, as follows. The same cortical neuronal cultures as described above are used. During Ca + measurements, unless otherwise stated the fluid bathing the neurons consists of Hanks' balanced salts: 137.6 mM NaCl, 1 mM NaHC03, 0.34 mM Na2HP04, 0.44mM
KH2P04, 5.36 mM KC1, 1.25 mM CaCl-, 0.5 mM MgS04, 0.5 mM MgCl2, 5 mM Hepes NaOH, 22.2 mM glucose, and phenol red indicator (0.001% v/v) ; pH 7.2. NMDA and other substances are usually applied to the neurons by pressure ejection after dilution in this bath solution. Neuronal
[Ca2+]i is analyzed with fura 2-acetoxy-methyl ester (AM) as described [Grynkiewicz, et al., J. Biol. Chem. 260:3440 (1985); Williams et al.. Nature 318:558 (1985); Connor et al., J. Neurosci. 21384 (1987); Connor et al., Science 240:649 (1988); Cohan et al., J. Neurosci. 23588 (1987); Mattson, et al., ibid. £:3728 (1989)]. After adding Eagle's minimum essential medium containing 10 μM fura 2-AM to the neurons, the cultures are incubated at 37°C in a 5% C02/95% air humidified chamber and then rinsed. The dye is loaded, trapped, and deesterified within 1 hour, as determined by stable fluorescence ratios and the effect of the Ca + ionophore ionomycin on [Ca2+]i is measured. During Ca + imaging, the cells are incubated in a solution of Hepes-buffered saline with Hanks' balanced salts. The [Ca+]i is calculated from ratio images that are obtained by measuring the fluorescence at 500 nm that is excited by 350 and 380 nm light with a DAGE MTI 66 SIT or QUANTEX QX-100 Intensified CCD camera mounted on a Zeiss Axiovert 35 microscope. Exposure time for each picture is 500 ms. Analysis is performed with a Quantex (Sunnyvale, CA) QX7-210 image-processing system. Since cells are exposed to ultraviolet light only during data collection (generally less than a total of 20 s per cell) , bleaching of fura 2 is minimal.
Nitroprusside Decreases the NMDA-Mediated Increase in the Intracellular Concentration of Ca
NMDA-receptor mediated neurotoxicity has been shown to involve an increase in intracellular Ca2+ concentration. The increase in [Ca ]i was documented in the following experiment. Intracellular Ca2+ was measured as described above. Application of lOμM NMDA produced a striking increase in [Ca2+]i [Fig. 2, columns 2-5(b) ] . Compared to control levels [Ca2+ = 50nM Col. 1(a)] obtained before the addition of NMDA, levels following
NMDA addition increased to 200nM. These results represent the average [Ca2+]i measurement of six independent neurons measured every two minutes for four trials. Using the same neurons, the [Ca2+]i was allowed to return to the control level, and the cultures were treated first with 5mM DTT for 5 minutes (and washed out) and then lOμM NMDA was applied repeatedly. This combined DTT and NMDA treatment produced an increase in [Ca2+]i levels which was even greater than that observed for NMDA treatment alone; specifically, an average level of 400nM free calcium ion concentration was measured. These results are shown in columns 6-8 (c) and represent the average measurement for the same six neurons measured every two minutes for three trials. Calcium levels were again allowed to return to control levels and the effect of nitroprusside on [Ca2+]i was tested in the same neurons whose NMDA receptors had been previously chemically reduced with 5mM DTT. Following treatment with 5mM nitroprusside for 5 minutes (and wash out) , lOμM NMDA did not evoke as great a Ca2+ response. Indeed, the free calcium ion concentration was very similar to that observed in control cultures (approximately 50nM averaged for the three trials at two minute intervals for the same six neurons) . These results are shown in columns 9-11 (d) .
Verification that the effect at issue involves the NMDA redox site can be provided as follows.
Maximal chemical reduction of the site by 0.5-5 mM dithiothreitol (DTT) prior to nitroprusside treatment increases NMDA responses (i.e., NMDA produces an increased intracellular calcium concentration (in part via ionic current) and neuronal death) , but nitroprusside (0.3-5 mM) prevents these effects. Pretreatment with a strong oxidizing agent 5-5-dithio-bis-2-nitrobenzoic acid (DTNB, 0.1-2 mM, administered in a parallel experiment in
place of DTT) blocks the effect of nitroprusside on NMDA evoked maximum [Ca2+]i increase and ionic current increase, although NMDA itself still maintains some effect. In other words, a maximal chemical oxidation with DTNB abrogates the effect of nitroprusside, strongly suggesting that nitroprusside is acting in the same manner under these conditions (i.e., as an oxidizing agent) because it has no further effect after DTNB oxidation of the redox modulatory site of the NMDA receptor-channel complex. It should be noted that once the redox modulatory site is oxidized or reduced, even after subsequent wash out of the redox agent, the site remains in this state until another effective redox agent is introduced. Therapy
To prevent neuronal damage, compounds of the invention may be administered by any of a number of routes in an amount sufficient to attenuate an NMDA- evoked ionic current or a rise in [Ca2+]i, or neurotoxicity. The compound may be included in a pharmaceutical preparation, using a pharmaceutical carrier (e.g., physiological saline); the exact formulation of the therapeutic mixture depends upon the route of administration. Preferably, the compound is administered orally or intravenously, but it may also be administered sublingually, by spray, by transdermal patch, or by ointment. The preferred compounds, nitroglycerine or their derivatives (including all those preparations commercially available, e.g., those listed in the Physician' ε Desk Reference (1991) under coronary vasodilators or under nitroglycerin or nitroglycerin intravenous and including isosorbide mononitrate, isosorbide dinitrate, nitroglycerin sublingual, NT-1, Niotrocor, Nitroderm, Nitrodisc, Nitro-dur, Nitro-Dur II, Nitrofilm, Nitrogard, Nitroglin, Nitropen, Tridil, and 6-
chloro-2-pyridylmethyl nitrate) are administered at 0.01- lOOOmg/day, in divided doses. Sodium nitroprusside — Na2[Fe(CN)5NO]-2H20 (from Elkins-Sinn, Inc., Cherry Hill NJ) or Nipride (from Roche, Nutley, NJ) — are administered intravenously at 0.5-10μg/min. Other nitric oxide-generating compounds, determined to be an effective neuroprotective agent by the assays described herein, is administered orally, intravenously, sublingually, by spray, or by transder al patch or ointment at a dosage suitable to reduce neuronal damage, or NMDA evoked ionic current or increased [Ca2+]i. Generally, such compounds are administered in dosages of 0.1-5 mg/day in divided doses. Treatment may be repeated as necessary to prevent or alleviate neurological injury. The compounds of the invention can be utilized to protect against a number of neurotoxic disorders caused by elevated levels of glutamate or related compounds. Such neurotoxic disorders include ischemia, hypoxia, hypoglycemia, trauma, epilepsy, Huntington's disease, and Alzheimer's disease and other neurodegenerative disorders. The method of the invention is'particularly preferred for the treatment of AIDS dementia and other neurological manifestations of the AIDS virus. The method may also be used for reduction of neuronal damage resulting from infection with other viruses which cause damage to the nervous system.
Other Embodiments The method described herein is useful for reducing neuronal injury in any mammal having NMDA receptors. Treatment of neuronal damage in humans is the preferred utility; but the method may also be employed successfully for veterinary purposes.
Claims
Claims 1. A medicament for reducing NMDA reσeptor- mediated neuronal damage in a mammal, comprising a nitric-oxide generating compound, or a physiologically acceptable salt thereof, in a concentration effective to cause such reduction.
2. A medicament for reducing NMDA receptor- mediated neuronal damage in a mammal, comprising nitroprusside, nitroglycerin, or a derivative of one of those compounds, in a concentration effective to cause such reduction.
3. The medicament of claim 1, wherein said compound is nitroprusside or a nitric oxide-generating derivative thereof.
4. The medicament of claim 1, wherein said compound is nitroglycerin or a nitric oxide-generating derivative thereof.
5. The medicament of claim 1 or claim 2, wherein said mammal is a human infected with a human immunodeficiency virus.
6. The medicament of claim 5, wherein said human manifests symptoms of the AIDS related complex or acquired immunodeficiency syndrome.
7. The medicament of claim 1 or claim 2 wherein said mammal suffers from a disorder selected from the group consisting of hypoxia, ischemia, trauma, hypoglycemia, seizures, stroke, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4510067A JPH06506690A (en) | 1991-04-19 | 1992-04-17 | Methods for blocking neuronal damage mediated by NMDA receptor complexes |
EP92910911A EP0581856B1 (en) | 1991-04-19 | 1992-04-17 | Method of preventing nmda receptor complex-mediated neuronal damage |
DE69229598T DE69229598T2 (en) | 1991-04-19 | 1992-04-17 | METHOD FOR PREVENTING NMDA RECEPTOR COMPLEX-MEDIATED NEURONAL DAMAGE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68896591A | 1991-04-19 | 1991-04-19 | |
US688,965 | 1991-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018112A1 true WO1992018112A1 (en) | 1992-10-29 |
Family
ID=24766524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/003196 WO1992018112A1 (en) | 1991-04-19 | 1992-04-17 | Method of preventing nmda receptor complex-mediated neuronal damage |
Country Status (7)
Country | Link |
---|---|
US (1) | US5234956A (en) |
EP (1) | EP0581856B1 (en) |
JP (2) | JPH06506690A (en) |
AT (1) | ATE182076T1 (en) |
DE (1) | DE69229598T2 (en) |
ES (1) | ES2134804T3 (en) |
WO (1) | WO1992018112A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018966A1 (en) * | 1993-02-26 | 1994-09-01 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system with active substances which represent sources of nitrogen oxide |
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
WO1996009038A2 (en) * | 1994-09-22 | 1996-03-28 | William Harvey Research Limited | Alteration of activity and/or levels of haem-oxygenase to control inflammation |
US5512457A (en) * | 1992-11-13 | 1996-04-30 | Immunex Corporation | Cytokine designated elk ligand |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
EP1050309A1 (en) * | 1998-01-30 | 2000-11-08 | Sumitomo Pharmaceuticals Company, Limited | Neurotrophic factor secretion promoters |
WO2001072291A2 (en) * | 2000-03-25 | 2001-10-04 | The Victoria University Of Manchester | Treatment of movement disorders with metabotropic glutamate receptor antagonist |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US8901171B2 (en) | 2010-01-27 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5721365A (en) * | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
US5455279A (en) * | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US6071876A (en) * | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5691423A (en) * | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5475007A (en) * | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
US5840759A (en) * | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
WO1995010267A1 (en) * | 1993-10-08 | 1995-04-20 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers |
US5648101A (en) * | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
US6310052B1 (en) | 1996-06-04 | 2001-10-30 | Queen's University At Kingston | Nitrate esters and their use for neurological conditions |
US20050137191A1 (en) * | 1996-06-04 | 2005-06-23 | Thatcher Gregory R. | Nitrate esters and their use for mitigating cellular damage |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US20040110691A1 (en) * | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
AR046314A1 (en) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | COMPOSITIONS THAT INCLUDE CYCLHEXILAMINES AND AMINOADAMANTANS |
WO2006096194A2 (en) | 2004-06-17 | 2006-09-14 | Merz Pharma Gmbh & Co. Kgaa | Drinkable immediate release tablet made with direct compression of memantine or neramexane |
EP2111858A1 (en) | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
WO2009152479A1 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases of trauma |
WO2009152483A2 (en) * | 2008-06-12 | 2009-12-17 | University Of Alabama Huntsville | Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
ES2625548T3 (en) | 2012-06-04 | 2017-07-19 | DiaMedica Therapeutics Inc. | Glycosylation isoforms of human tissue calicrein-1 |
WO2018165551A1 (en) | 2017-03-09 | 2018-09-13 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4806543A (en) * | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
EP0486621A4 (en) * | 1989-08-09 | 1993-03-31 | The Children's Medical Center Corporation | Nmda oxidizing agents for protecting neurons from injury |
US5091391A (en) * | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
-
1992
- 1992-04-17 WO PCT/US1992/003196 patent/WO1992018112A1/en active IP Right Grant
- 1992-04-17 ES ES92910911T patent/ES2134804T3/en not_active Expired - Lifetime
- 1992-04-17 EP EP92910911A patent/EP0581856B1/en not_active Expired - Lifetime
- 1992-04-17 AT AT92910911T patent/ATE182076T1/en active
- 1992-04-17 DE DE69229598T patent/DE69229598T2/en not_active Expired - Lifetime
- 1992-04-17 JP JP4510067A patent/JPH06506690A/en active Pending
- 1992-09-22 US US07/949,342 patent/US5234956A/en not_active Expired - Lifetime
-
2005
- 2005-12-16 JP JP2005362538A patent/JP2006117693A/en active Pending
Non-Patent Citations (1)
Title |
---|
Merck Index 9th Ed. (1976), page 858, No. 6429. * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
US5512457A (en) * | 1992-11-13 | 1996-04-30 | Immunex Corporation | Cytokine designated elk ligand |
US5627267A (en) * | 1992-11-13 | 1997-05-06 | Immunex Corporation | Cytokine designated elk ligand |
US5670625A (en) * | 1992-11-13 | 1997-09-23 | Immunex Corporation | Elk ligand fusion proteins |
US5728813A (en) * | 1992-11-13 | 1998-03-17 | Immunex Corporation | Antibodies directed against elk ligand |
WO1994018966A1 (en) * | 1993-02-26 | 1994-09-01 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system with active substances which represent sources of nitrogen oxide |
US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US6596852B2 (en) | 1994-07-08 | 2003-07-22 | Immunex Corporation | Antibodies that bind the cytokine designated LERK-5 |
US6492140B2 (en) | 1994-07-08 | 2002-12-10 | Immunex Corporation | Polynucleotides encoding cytokine designated LERK-5 |
US6479459B1 (en) | 1994-07-08 | 2002-11-12 | Immunex Corporation | Cytokine designated lerk-5 |
US6066333A (en) * | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
WO1996009038A3 (en) * | 1994-09-22 | 1996-06-13 | William Harvey Research Limite | Alteration of activity and/or levels of haem-oxygenase to control inflammation |
WO1996009038A2 (en) * | 1994-09-22 | 1996-03-28 | William Harvey Research Limited | Alteration of activity and/or levels of haem-oxygenase to control inflammation |
EP1050309A4 (en) * | 1998-01-30 | 2002-10-23 | Sumitomo Pharma | Neurotrophic factor secretion promoters |
EP1050309A1 (en) * | 1998-01-30 | 2000-11-08 | Sumitomo Pharmaceuticals Company, Limited | Neurotrophic factor secretion promoters |
WO2001072291A2 (en) * | 2000-03-25 | 2001-10-04 | The Victoria University Of Manchester | Treatment of movement disorders with metabotropic glutamate receptor antagonist |
WO2001072291A3 (en) * | 2000-03-25 | 2002-02-21 | Univ Manchester | Treatment of movement disorders with metabotropic glutamate receptor antagonist |
US8901171B2 (en) | 2010-01-27 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
Also Published As
Publication number | Publication date |
---|---|
ATE182076T1 (en) | 1999-07-15 |
DE69229598D1 (en) | 1999-08-19 |
US5234956A (en) | 1993-08-10 |
EP0581856B1 (en) | 1999-07-14 |
JP2006117693A (en) | 2006-05-11 |
EP0581856A4 (en) | 1994-03-02 |
ES2134804T3 (en) | 1999-10-16 |
EP0581856A1 (en) | 1994-02-09 |
DE69229598T2 (en) | 1999-11-04 |
JPH06506690A (en) | 1994-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5234956A (en) | Method of preventing NMDA receptor complex-mediated neuronal damage | |
US5455279A (en) | Regimen method of mediating neuronal damage using nitroglycerine | |
Blaise et al. | Nitric oxide, cell signaling and cell death | |
Contestabile et al. | Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches | |
US5587384A (en) | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity | |
Sucher et al. | Molecular basis of glutamate toxicity in retinal ganglion cells | |
Tieu et al. | D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease | |
Kis et al. | Diazoxide induces delayed pre‐conditioning in cultured rat cortical neurons | |
Medvidovic-Grubisic et al. | Hypermagnesemia disturbances in rats, NO-related: pentadecapeptide BPC 157 abrogates, L-NAME and L-arginine worsen | |
Hui et al. | Ketone bodies protection against HIV‐1 Tat‐induced neurotoxicity | |
Kurkin et al. | Activity modulation of various nitric oxide syntases as an approach to endothelial dysfunction therapy | |
JPH06506212A (en) | Use of riboflavin for the treatment of HIV viral diseases, herpes, retinitis pigmentosa and malaria | |
US20030100482A1 (en) | NMDA oxidizing agents for protecting neurons from injury | |
Schoonover et al. | Hemodynamic and cardiovascular effects of nitric oxide modulation in the therapy of septic shock | |
EP1383497B1 (en) | Carbonic anhydrase activators for enhancing learning and memory | |
US6071876A (en) | Method of preventing NMDA receptor complex-mediated neuronal damage | |
US6043268A (en) | Agent for treatment of viral infections | |
Grobecker et al. | Effect of prolonged treatment with adrenergic neuron blocking drugs on sympathoadrenal reactivity in rats | |
Shukla | Nitric oxide in neurodegeneration | |
US20160354330A1 (en) | Treatment of levodopa-induced dyskinesias | |
US20220031719A1 (en) | Antiviral therapeutic drug combinations | |
US20090156649A1 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
US20040147604A1 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
EP1935414A2 (en) | Carbonic anhydrase activators for enhancig learning and memory | |
Childers Jr | Patent Update: Cerebral Anti-lschaemic Agents: Recent Advances, June Through December, 1991 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992910911 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992910911 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992910911 Country of ref document: EP |